Signals Inbox·August 22, 2026·NeuroTech

Neuralink vs Synchron: who is ahead now?

Neuralink is ahead right now because it is extracting richer, more useful control from the brain, while Synchron remains the strongest challenger thanks to easier surgery, stronger long-term safety evidence and a more hospital-friendly path to scale.

Q1Why does everyone compare Neuralink with Synchron?

Neuralink and Synchron keep getting compared because they are chasing the same first real BCI market: giving people with severe paralysis direct control of computers and other devices.

Both companies have fully implanted systems in human trials. Both decode brain activity into digital commands. Both are starting with people who have lost movement through conditions such as spinal cord injury or ALS. And both ultimately need to prove that a brain implant can become something patients use at home rather than an experiment they operate during supervised research sessions.

Their approaches, however, could hardly be more different.

Neuralink puts tiny electrode threads directly into the cortex using its R1 surgical robot. The current N1 system records through 1,024 electrodes. Synchron reaches the brain through the jugular vein and leaves its Stentrode inside a blood vessel next to the motor cortex. The first-generation Stentrode has 16 electrodes and can be implanted without open-brain surgery.

That creates the real rivalry. Neuralink is trying to get much more information from the brain. Synchron is trying to reach the brain much more easily.

The comparison has also become more relevant lately because both companies have moved beyond their original tiny trials. Neuralink's latest company-wide update reported 21 implanted participants. Synchron has opened new 10-person studies in the United States, Canada and Australia. We are now getting enough human evidence to compare two different ways of turning implanted BCIs into actual medical products.

Q2Why isn't the answer obvious?

The answer stays close because Neuralink currently looks better as a BCI, while Synchron looks easier to turn into a routine medical procedure.

If we only asked which system appears capable of extracting richer commands from the brain, we would choose Neuralink fairly quickly. It records much closer to individual neurons, uses far more electrodes and has shown continuous cursor control, gaming, computer work and robotic-arm control.

Synchron changes the question. Its implant goes through a blood vessel using catheter techniques that doctors already understand. The clinical procedure takes roughly two hours, according to the company, and most trial participants can leave hospital the following day. That could become a huge advantage if thousands of patients eventually want these devices.

There is another complication: neither company has a commercially approved BCI. We have no useful revenue, market-share, renewal-rate or customer-spending comparison. The market is still being created.

So we have to judge what actually determines leadership at this stage: how many people have received the systems, what those people can do, how safe the implants look over time, how difficult implantation is, how quickly trials are expanding, how close each company is to regulatory approval and whether the underlying architecture can eventually scale.

Those scoreboards produce different winners.

Q3Who has actually implanted more people?

Neuralink is ahead today on confirmed human implant scale, although Synchron has recently started a much larger expansion phase.

The latest company-wide number Neuralink has publicly confirmed is 21 participants. Its pace accelerated sharply after the first three implants: Neuralink's own surgery timeline shows one procedure in the first half of 2024, two in the second half, four in the first half of 2025 and 13 in the second half.

That progression matters more than the headline total. The company went from an occasional first-in-human procedure to multiple implants per month during parts of 2025. It also showed that the procedure could travel: seven participants were implanted in Neuralink's British program at UCLH within roughly three months.

Synchron's clean historical count comes from 10 first-generation participants: four in the Australian SWITCH study and six in the U.S. COMMAND study. We have found no equally clear current company-wide number that confirms how many additional patients from its newest studies have already been implanted, so we would rather leave those people out than count planned enrollment as completed procedures.

The recent trial registrations still change the picture. ClinicalTrials.gov currently lists 10 planned participants in the U.S. INTENT trial, 10 in FOCUS-CAN and another 10 in FOCUS-AUS. The Canadian and Australian studies have started, while INTENT is recruiting.

Synchron therefore has room to add up to 30 participants across this new wave. Until those implants actually happen, Neuralink keeps the lead.

Neuralink vs Synchron: confirmed human implant scale

Q4Which implant lets patients do more today?

Neuralink currently gives users richer direct computer control, and this is the clearest technical advantage in the comparison.

The hardware difference is enormous. Neuralink's N1 records through 1,024 electrodes spread across 64 flexible threads placed in the cortex. Synchron's first-generation Stentrode uses 16 electrodes positioned inside a blood vessel. That is a 64-fold difference in electrode count, although electrode count alone never tells us how much useful information reaches the computer.

The behavior we see from patients is more convincing.

Neuralink reports that its eighth participant reached 10.39 bits per second in Webgrid, the company's standardized cursor-control task. Other participants have used the system for browsing, writing, games, computer-aided design, study and work. The CONVOY program has also extended the implant into control of an assistive robotic arm.

Synchron has produced solid results of a different kind. In the peer-reviewed SWITCH study, four participants achieved an average 93.9% selection accuracy and 16.6 correct characters per minute. They used the system for texting, email, shopping and financial tasks. One participant could make selections using the BCI without the eye tracker that was normally used to move the cursor.

We should resist putting Synchron's characters per minute beside Neuralink's bits per second as though they were the same benchmark. They came from different interfaces and different tasks.

What we can say confidently is that Neuralink has shown more continuous, higher-dimensional control. Synchron's first-generation system has mostly shown reliable detection of a smaller set of intentions.

Neuralink N1 vs Synchron Stentrode: capability today

Q5Is Synchron's blood-vessel approach actually the smarter design?

Synchron has the smarter implantation route today, but Neuralink's harder surgery currently buys a meaningful performance advantage.

Synchron designed the Stentrode around a simple idea: doctors already know how to navigate catheters through blood vessels, so why require an open-brain operation if useful neural signals can be recorded from inside a vein?

The result is appealing. The implant travels through the jugular vein to a vessel beside the motor cortex. Synchron says the procedure used in its trials takes around two hours and most participants go home the next day. The COMMAND study reported successful deployment over the target motor cortex in all six participants.

That gives Synchron a very obvious path into existing hospitals. Neurointerventional specialists already perform vascular procedures at scale. Synchron can build around that infrastructure rather than asking hospitals to buy a completely new type of surgical platform.

Neuralink has chosen the opposite engineering trade-off. Its flexible threads need to enter the cortex, and they are too small to place reliably by hand. The company therefore built the R1 robot specifically to do the insertion.

This creates more operational work, but we can already see why Neuralink accepted it. Direct cortical access provides much richer control.

Synchron's own product roadmap is revealing here. Its latest financing is partly going toward a next-generation high-channel interface. In plain English, Synchron wants more neural information while keeping the catheter advantage.

That is probably the right move. If it can raise bandwidth substantially without making the procedure much harder, this could become the strongest architecture in the market.

Q6Who has the better safety record so far?

Synchron still has the stronger safety record we can independently inspect, even though Neuralink now says it has operated on more people.

Synchron's advantage comes mainly from the depth of its published evidence.

Its SWITCH study was published in JAMA Neurology after four participants completed 12 months of follow-up. Researchers reported no device-related serious adverse events, no target-vessel occlusion and no meaningful device migration. Signal bandwidth also remained stable across the year.

The six-person U.S. COMMAND study later completed its 12-month primary safety follow-up. Synchron says all six participants met that endpoint without a serious brain or vascular adverse event attributed to the device.

We also now have a much longer individual case. Rodney Gorham has lived with a Synchron implant for around five years. A single person cannot establish five-year safety for the whole product, but this is still unusually valuable evidence in a field where almost every human implant is young.

Neuralink's record is encouraging but less mature in published form. The company said in its latest broad participant update that it had recorded zero serious device-related adverse events. Its first participant did experience partial retraction of some electrode threads, which reduced the number of useful electrodes before software changes recovered performance. Neuralink then modified its implantation approach and reported better stability in later participants.

The gap here is mainly one of evidence quality. Synchron lets us look at a peer-reviewed cohort with defined outcomes and long follow-up. Neuralink has a larger and rapidly growing human experience, but much of what we know still comes through the company's own updates.

We give Synchron this one fairly clearly.

Q7Who is closer to FDA approval?

Synchron is closer to the traditional FDA finish line today, although commercial approval still looks some distance away for both companies.

Synchron entered U.S. human testing earlier. The Stentrode received FDA Breakthrough Device designation in 2020 and authorization for the COMMAND early-feasibility study in 2021. That six-person study has since completed its primary 12-month safety evaluation.

Neuralink received permission to begin its first U.S. human study later and started PRIME in 2024. ClinicalTrials.gov still describes PRIME as an early feasibility study. The company has expanded into additional programs, including CONVOY for assistive devices and VOICE for communication restoration.

Neuralink has also picked up FDA Breakthrough Device designations for speech restoration and its Blindsight vision program. That gives the company more regulatory paths, though Breakthrough status mainly helps interaction with the FDA and does not mean that a device is close to approval.

Synchron's newest U.S. study is important for judging how big its lead really is. INTENT still targets only 10 participants and is registered as an early feasibility study. Synchron has spent longer in the clinic, yet it has not publicly leapt into a huge pivotal study.

That makes the race closer than headlines sometimes suggest.

Synchron has the regulatory lead. We would describe it as meaningful rather than overwhelming.

Q8Do people actually use these implants outside the lab?

Yes, both Neuralink and Synchron have moved into real at-home use, but Neuralink currently shows more intensive day-to-day computer use.

Neuralink's early three-person cohort accumulated more than 4,900 hours of Telepathy use across more than 670 combined implant-days. Those hours included both research sessions and independent everyday use, so we should avoid treating the total as pure voluntary usage.

The newer participant stories are more useful. Neuralink says Sebastian, a medical student with a spinal cord injury, has used the implant for as much as 17 hours in a day while reading papers, taking notes and preparing for exams. Other participants use Telepathy for work, gaming, communication and creative software.

Synchron's home-use evidence goes back much further. SWITCH participants used their systems outside the clinic for texting, email, shopping and personal finance. Rodney Gorham has continued working with his Stentrode years after implantation as ALS progressively reduced his physical abilities.

His experience also exposes a problem that polished BCI demos can hide: mental effort. Wired's recent account of Gorham's fifth year with the implant describes how demanding control can become as his disease progresses.

This is where the next generation of evidence needs to improve. We want to know how many hours people voluntarily use these systems six months after implantation, how often they fall back to eye tracking or voice control, which activities they genuinely prefer doing with the BCI and whether usage rises or falls over time.

Neuralink looks stronger on intensity today. Synchron tells us more about durability.

Q9Does Synchron's Apple integration give it a real edge?

Synchron has a real distribution advantage with Apple because its BCI can increasingly behave like a normal input device rather than a standalone experimental computer system.

Synchron demonstrated native thought-based iPad control through Apple's BCI Human Interface Device protocol. A user with ALS could move through the operating system, open applications and compose text without relying on his hands.

Apple's own developer documentation now defines a BCI HID standard that allows compatible brain interfaces to send commands such as pointer movement, button presses and keyboard events. It can also send information back from the Apple device to the BCI.

This is much more useful than a promotional partnership where two companies put their logos on the same announcement.

If the protocol spreads, Synchron can connect its neural decoder to an existing ecosystem of iPhones, iPads, accessibility features and applications. Software developers do not need to build a special Synchron version of every app.

The company has followed the same direction with Apple Vision Pro and Alexa, so we can see a consistent strategy: let other companies build the devices and applications while Synchron becomes the input layer.

Neuralink takes a much more vertically integrated approach. It builds the implant, surgical robot, neural decoder, user software and much of the surrounding experience. That gives it tighter control over performance but leaves more of the stack on Neuralink's shoulders.

Synchron wins the distribution question for now.

Q10What is holding BCIs back right now: weak performance or difficult surgery?

Right now, useful performance is the bigger bottleneck, which favors Neuralink slightly.

People with paralysis already have other ways to interact with computers: eye trackers, switches, voice systems and specialized controllers. An implanted device has to offer enough extra independence to justify surgery, training and years of living with hardware inside the body.

Synchron makes the surgery much easier, but patients still undergo an invasive medical procedure. The Stentrode also brings vascular constraints and antithrombotic treatment considerations. A simpler implant only becomes compelling when the resulting control is valuable enough.

Neuralink is attacking that value threshold aggressively. Continuous cursor movement, faster digital control, attempted handwriting or finger-movement decoding, robotic-arm operation and the newer VOICE program all push toward tasks where a richer signal could transform what a person can do.

Once BCI performance becomes consistently excellent, the bottleneck could flip very quickly.

Imagine two systems that let a patient control a computer equally well. One requires intracortical implantation by a dedicated robot; the other goes through a vein with a catheter. Synchron would suddenly have the easier commercial story.

We're just not there yet. The field is still trying to establish how much useful control an implant can provide.

That gives Neuralink's bandwidth-first approach more weight today than it may deserve five years from now.

Q11Who is improving faster lately?

Neuralink has been moving the core BCI forward faster, while Synchron has concentrated more on making its existing interface easier to deploy and connect.

Neuralink began with cursor control and has since pushed the same implant toward robotic arms and communication. CONVOY lets existing participants control assistive devices such as a robotic arm. VOICE is testing whether intended speech can be decoded into text or audio. The company also has a separate future program around vision restoration.

Its most recent Telepathy update included something technically interesting beyond cursor movement: a participant typing by imagining finger movements. Neuralink says the communication work is eventually targeting conversational speeds of around 140 words per minute. That target remains unproven, but it shows where the architecture is heading.

Synchron's recent progress has been strongest around accessibility, software and clinical deployment. It connected the Stentrode to Apple's BCI HID framework, opened new trials in three countries and is developing a higher-channel next-generation system.

The split is pretty clear. Neuralink has lately been widening what the brain interface itself can control. Synchron has been widening where its interface can be used and how easily patients can receive it.

For an early BCI market, we give Neuralink the product-velocity edge because adding new neural capabilities changes the ceiling of the product more than adding another compatible device.

Q12Does Neuralink simply have too much money for Synchron to keep up?

Neuralink has a huge financing advantage today, but Synchron has enough capital to remain a serious competitor.

Neuralink raised $650 million in its Series E. Synchron's latest Series D brought in $200 million and lifted its disclosed cumulative funding to $345 million.

Neuralink's latest round alone was therefore 3.25 times larger than Synchron's latest round and almost twice Synchron's entire disclosed funding history.

Here, that difference matters a lot. Neuralink is simultaneously developing electrodes, custom implant electronics, neural-decoding software, charging hardware, manufacturing, a surgical robot and several clinical programs. Every additional patient also brings surgery, training and long follow-up.

Synchron has a lighter infrastructure model because it can lean on existing catheter-based medicine, but it is funding two generations at once: commercial development of the current Stentrode and a more ambitious high-channel platform.

Synchron does have strong backers, including ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, Qatar Investment Authority and Australia's National Reconstruction Fund. Its $200 million round is large enough that funding itself should not become the immediate bottleneck.

Still, Neuralink can afford more parallel experiments and more mistakes. In frontier medical hardware, that is a real advantage.

Q13Which company has built the harder advantage to copy?

Neuralink has built the broader technical moat, while Synchron's best defensive asset is the procedure itself.

A competitor trying to reproduce Neuralink would need more than a brain implant. Neuralink has developed flexible electrode threads, microfabrication, wireless implanted electronics, neural-decoding software and the R1 insertion robot. Those pieces have been designed around one another.

The surgical robot is especially important. Neuralink's threads are so small and flexible that their technical advantage depends on having a reliable way to put them into the cortex. Improving the robot therefore improves the implant, and every additional human procedure gives the company more experience with anatomy, placement and failure modes.

Synchron's moat comes from a narrower piece of the stack, but it could become extremely powerful. The company has spent roughly a decade learning how to record useful neural activity from inside cerebral blood vessels and how the vessel remodels around an implanted device.

The next-generation Synchron system could decide this question.

If Synchron manages to add far more recording channels while preserving catheter implantation, competitors would have to match two advantages at once: high neural bandwidth and a procedure compatible with existing hospitals.

Today, Neuralink owns more proprietary pieces of the puzzle. Synchron has a chance to own the better architecture if its high-channel program works.

Q14Could Paradromics or Precision make the Neuralink-Synchron rivalry irrelevant?

Yes, because several competitors are now attacking the exact trade-off that separates Neuralink from Synchron.

Paradromics is the most obvious threat to Neuralink's side of the race. Its Connexus system also uses an intracortical interface and targets high-data-rate communication. The company has moved into human clinical work, which means Neuralink no longer occupies the high-bandwidth implanted category alone.

Precision Neuroscience is pursuing another route. Its Layer 7 cortical interface places a high-density array on the brain's surface. The FDA has cleared its 1,024-electrode array for temporary use for up to 30 days, although that clearance should not be confused with approval for a permanent commercial BCI.

Both matter because the winning architecture may end up somewhere between Neuralink and Synchron.

A system that collects much richer signals than today's Stentrode while avoiding Neuralink's penetrating threads could make the current two-company comparison look too narrow.

For now, neither Paradromics nor Precision has matched the combination of home use, participant history and public human demonstrations accumulated by Neuralink and Synchron. They are challengers rather than leaders.

But we would watch them closely. The BCI race is young enough that the dominant technical architecture is still unsettled.

Q15Who is better positioned for the next five years?

Neuralink has the stronger long-term position today because its architecture gives it more room to expand beyond basic computer control.

A brain interface becomes much more interesting when the same underlying platform can support several types of output.

Neuralink is already testing that idea. Telepathy covers computers and phones. CONVOY extends control into physical assistive devices. VOICE targets communication for people who have lost speech. Blindsight points toward a future input back into the nervous system rather than simply reading motor intent.

Some of those programs are extremely early, so we would avoid giving Neuralink credit for products that do not exist yet. Still, the core point holds: direct cortical access gives the company a larger technical playground.

Synchron's five-year path is easier to picture commercially. It can focus on one extremely useful problem, reliable digital control for people with severe motor impairment, and try to make implantation routine enough for mainstream hospitals.

That could produce the first broadly deployed BCI even if Neuralink remains technically more impressive.

The variable we care about most is Synchron's next high-channel platform. Its current generation proves that endovascular recording works. The next one has to show how far that approach can be pushed.

If Synchron starts producing continuous high-performance control from a catheter-delivered implant, we would reconsider the long-term ranking quickly.

Until then, Neuralink has the higher ceiling.

Q16Who is winning Neuralink vs Synchron right now?

Neuralink is winning Neuralink vs Synchron right now, with a real but still reversible lead.

We give Neuralink the overall edge because the hardest problem at this stage is still making an implanted BCI useful enough to justify having one. Neuralink currently leads there. Its users have shown richer continuous control, the platform has moved into robotic-arm use and speech research, and its implantation pace accelerated sharply during the last full year for which the company disclosed surgeries.

Synchron wins several areas that could eventually become more important. It has the easier implantation route, stronger peer-reviewed long-term human evidence, earlier U.S. regulatory experience and the better integration strategy with existing consumer devices.

But those strengths have not yet produced commercial approval or clearly superior patient functionality.

As seen above, the latest clean company-wide count we can verify from Neuralink remains 21 participants, compared with Synchron's 10 established first-generation recipients. Synchron's three new 10-person studies make that gap worth watching closely, but planned enrollment cannot count as market progress until patients actually receive the device.

The next year or two should make the comparison much easier.

For Synchron, we want to see three things: those new studies filling with patients, the strong safety profile surviving at larger scale, and concrete evidence that its next-generation interface can deliver richer continuous control.

For Neuralink, the questions are simpler. Can it publish stronger cohort-level human evidence? Can its electrodes remain stable for years rather than months? And can hospitals repeat the robot-assisted operation frequently enough that the surgical model starts looking routine?

If Neuralink answers those questions well, its current technical lead becomes much harder to attack.

If Synchron sharply improves bandwidth while keeping its blood-vessel procedure, the balance could flip.

Today, though, Neuralink is ahead because it is doing more of the thing patients ultimately need a BCI to do: turning brain activity into useful control.

Neuralink vs Synchron: who leads by criterion